Application of sevoflurane
Through the selective inhibition of GluN2D subunit and GluN1/GluN2D receptors by sevoflurane, the problem of delayed and side effects of existing antidepressants in patients with refractory depression and major depression is solved, and rapid and long-lasting anti-anti-depressant drugs are achieved Depressive effect reduces the difficulty of treatment and disability rate.
Patent Information
- Application Number
- CN202310503888.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-06
- Publication Date
- 2024-11-08
AI Technical Summary
Existing antidepressants have delayed effects on patients with refractory depression and major depression, and have side effects, which cannot effectively and quickly take effect, increasing the difficulty of treatment and disability rate.
Sevoflurane is used as a drug to selectively inhibit the GluN2D subunit and GluN1/GluN2D receptor, and use its selective inhibitory effect on NMDA receptors to provide rapid antidepressant treatment and avoid hallucinogenic, dissociation and addictive side effects.
Sevoflurane can take effect quickly, significantly reduce depression symptoms, and the effect can last for more than 2 weeks. It is suitable for patients with refractory depression, major depression and ineffective ketamine, reducing the difficulty of treatment and disability rate.
Smart Images

Figure BDA0004214892350000061 
Figure BDA0004214892350000062 
Figure BDA0004214892350000071
Abstract
Description
Technical Field
[0001] The present invention relates to the field of depression treatment, specifically to the use of sevoflurane in treating depression, and particularly to the use of sevoflurane in treating patients with abnormal GluN2D subunit or abnormal GluN1 / GluN2D receptor. Background Art
[0002] Depression is the most common mental disorder in humans, with a high global prevalence and great social harm. It is a serious global public health problem. However, the current first-line antidepressants mainly target the monoamine neurotransmitter system, and generally have shortcomings such as delayed onset, ineffectiveness for patients with refractory depression, and serious toxic and side effects. Generally, monoamine antidepressants take 2-3 weeks to take effect, and the full effect time is 4-6 weeks. During this period, the patient's condition is unstable, which is extremely unfavorable for patients with major depression with a high risk of suicide. In addition, the efficacy of a certain antidepressant for the first time in patients with depression is less than 50%, and the efficacy of changing to other antidepressants after the first treatment failure is reduced to 13%. Most patients are converted into refractory depression (TRD) because their condition cannot be controlled, which significantly increases the difficulty of treatment and the rate of mental disability. Therefore, there is still a large unmet medical need for clinical drug treatment of depression, and the development of fast-acting antidepressants and the exploration of the mechanism of action of fast-acting antidepressants are still of great clinical significance. Summary of the invention
[0003] The object of the present invention is to provide the application of sevoflurane.
[0004] The first aspect of the present invention provides a use of sevoflurane for preparing a drug for treating or preventing depression; or for preparing a drug for selectively inhibiting NMDA receptors containing GluN2D subunits.
[0005] In another preferred embodiment, the depression is selected from: drug-resistant depression, refractory depression, and depression that is ineffective with monoamine oxidase inhibitors.
[0006] In another preferred embodiment, the severe depression is severe depression with suicidal tendency.
[0007] In another preferred embodiment, the drug is used to treat patients who are ineffective with monoamine oxidase inhibitors.
[0008] In another preferred embodiment, the drug is used to treat patients who have received ketamine treatment but have not responded, or patients who have excessive side effects from ketamine treatment.
[0009] In another preferred embodiment, the drug is used to treat patients with abnormal GluN2D subunit or abnormal GluN1 / GluN2D receptor.
[0010] In another preferred embodiment, the sevoflurane is used to inhibit GluN1 / GluN2D receptors.
[0011] In another preferred embodiment, the abnormal GluN2D subunit refers to an increase in the GluN2D subunit.
[0012] In another preferred embodiment, the abnormal GluN1 / GluN2D receptor refers to an increase in GluN1 / GluN2D receptor.
[0013] In another preferred embodiment, the concentration of sevoflurane is 1% sub-anesthetic concentration. Herein, 1% sub-anesthetic concentration is a volume percentage, and sevoflurane is mixed with O2 / N2.
[0014] In another preferred embodiment, sevoflurane is administered by inhalation or intravenous administration.
[0015] In a second aspect, the present invention provides a method for inhibiting the activity of GluN2D subunit in vitro, the method comprising contacting cells expressing GluN2D subunit with sevoflurane, thereby inhibiting the activity of GluN2D subunit.
[0016] In another preferred embodiment, the method is non-therapeutic and non-diagnostic.
[0017] The third aspect of the present invention provides a method for inhibiting the activity of GluN1 / GluN2D receptors in vitro, characterized in that the method comprises contacting cells expressing GluN1 / GluN2D receptors with sevoflurane, thereby inhibiting the activity of GluN2D subunits.
[0018] In another preferred embodiment, the method is non-therapeutic and non-diagnostic.
[0019] Depression has a high incidence rate and strong disability, especially major depression (MDD), which is more harmful. However, clinical first-line antidepressants mainly target the monoamine neurotransmitter system, and generally have defects such as delayed onset and ineffectiveness. The present invention finds that sevoflurane has a selective inhibitory effect on NMDAR containing GluN2D subunits. Subanesthetic doses of sevoflurane exert rapid antidepressant effects by inhibiting NMDAR containing GluN2D subunits, and do not produce side effects such as hallucinations, dissociation and addiction. It can be used to treat depression patients who have failed first-line antidepressant treatment and are ineffective with ketamine. It has a rapid onset of action, prevents the condition from being transformed into refractory depression due to uncontrolled illness, and reduces the difficulty of treatment and mental disability rate to a certain extent.
[0020] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Each feature disclosed in the specification can be replaced by any alternative feature that provides the same, equal or similar purpose. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The effect of repeated exposure to different concentrations of sevoflurane on the motor ability of mice (open field test). (a) Total distance traveled every 2 minutes within 10 minutes; (b) Percentage of central distance. Two-way ANOVA with repeated measurement analysis; Compared with the control group, *p<0.05.
[0022] Figure 2 The effect of different concentrations of sevoflurane on the immobility time in the forced swimming test (forced swimming test) is shown. (a) Immobility time measured 24 hours after sevoflurane intervention (the inserted number represents the number of mice in each group participating in the test). (b) Forced swimming test: Immobility time measured 1 week after sevoflurane intervention (the inserted number represents the number of mice in each group participating in the test). Two-way ANOVA, compared with the control group, *p<0.05, **p<0.01.
[0023] Figure 3 The effect of a single exposure to subanesthetic concentration (1%) of sevoflurane on the motor ability of mice (open field test). (a) Total distance traveled every 2 minutes within 10 minutes; (b) Percentage of central distance. Two-way ANOVA, compared with the control group, *p<0.05.
[0024] Figure 4 The figure shows the effect of a single exposure to subanesthetic concentration (1%) of sevoflurane on the depressive-like behavior of mice (forced swimming test). Two-way ANOVA, compared with the control group, *p<0.05.
[0025] Figure 5 The effect of subanesthetic concentration (1%) of sevoflurane on the open field test of CMS mice is shown. (a) Total distance traveled within 10 minutes. (b) Percentage of central distance traveled. The inserted numbers represent the number of mice in each group participating in the test. Two-way ANOVA, compared with the control group, *p<0.05, **p<0.01; compared with the CMS group, # p<0.05, ## p<0.01.
[0026] Figure 6The percentage of sucrose water intake increased by subanesthetic concentration (1%) of sevoflurane is shown. The inserted numbers represent the number of mice in each group involved in the test. Two-way ANOVA, compared with the control group, *p<0.05, **p<0.01; compared with the CMS group, # p<0.05, ## p<0.01.
[0027] Figure 7 It shows that subanesthetic concentration (1%) of sevoflurane reduces the immobility time of forced swimming. Two-way ANOVA, compared with the control group, *p<0.05, **p<0.01; compared with the CMS group, # p<0.05, ## p<0.01.
[0028] Figure 8 It is shown that sevoflurane selectively inhibits NMDA receptors containing the GluN2D subunit in HEK 293 cells. ad Representative images of whole-cell voltage clamp recordings: (a) GluN1 / GluN2A, (b) GluN1 / GluN2B, (c) GluN1 / GluN2C, (d) GluN1 / GluN2D. e is a concentration-effect relationship diagram.
[0029] Fig. 9 The co-localization of mPFC GluN2D mRNA and interneurons is shown. gad67 is a marker for interneurons, and vglu1 is a marker for pyramidal neurons.
[0030] Fig.10 The effect of repeated exposure to 1% sevoflurane on the motor ability of mice after pretreatment with MK 801 and QNZ 46 is shown. The data were measured 30 minutes after repeated exposure to 1% sevoflurane. Two-way repeated measures ANOVA, compared with the control group, *p<0.05.
[0031] Fig.11 The effect of repeated exposure to 1% sevoflurane on the immobility time of forced swimming in mice after pretreatment with MK 801 and QNZ 46 is shown. The data were measured 30 minutes after repeated exposure to 1% sevoflurane. Two-way repeated measures ANOVA, compared with the group receiving only DMSO, *p<0.05, **p<0.01.
[0032] Fig.12 The effect of repeated exposure to 1% sevoflurane on the immobility time of the tail suspension test in mice after pretreatment with MK 801 and QNZ 46 is shown. The data were measured 30 minutes after repeated exposure to 1% sevoflurane. Two-way repeated measures ANOVA, compared with the group receiving only DMSO, *p<0.05, **p<0.01.
[0033] Fig.13The antidepressant effect of sevoflurane is shown to be associated with its selective inhibition of NMDARs containing GluN2D subunits. The figures show: the effect of 1.0 mM sevoflurane on the total APs firing rate (a) and the burst firing rate (c) of interneurons; the effect of 3 μM QNZ46 on the total APs firing rate (b) and the burst firing rate (d) of interneurons; the effect of 1.0 mM sevoflurane on the total APs firing rate of pyramidal neurons (e); the effect of 3 μM QNZ 46 on the total APs firing rate of pyramidal neurons (f). The inserted numbers represent the number of cells recorded by whole-cell patch clamp. Two-way ANOVA with repeated measurement analysis, *p<0.05 compared with the baseline value; #p<0.05 compared with 1.0 mM sevoflurane or 3 μM QNZ 46. DETAILED DESCRIPTION
[0034] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods for which specific conditions are not indicated in the following examples are usually performed under conventional conditions (such as the conditions described in Sambrook et al., Molecular Cloning: Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989)) or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and weight parts.
[0035] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.
[0036] Example 1
[0037] 1. Experimental Materials
[0038] 1.1 Experimental animals
[0039] C57BL / 6 mice (Shanghai Shrek Laboratory Animal Co., Ltd.), male, 8 weeks old, weighing 20-25 g
[0040] Mice were raised in a standard environment, 5 per cage, with a regular circadian rhythm (12 / 12 h), and adequate food and water. All procedures were in accordance with the relevant regulations of the Animal Care Committee (IACUC) of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
[0041] 1.2 Medicines
[0042]
[0043] 1.3 Experimental Reagents
[0044]
[0045]
[0046] 1.4 Experimental consumables
[0047]
[0048] 1.5 Experimental Instruments
[0049]
[0050]
[0051] 2. Experimental Methods
[0052] 2.1 Sevoflurane administration method
[0053] The mice were placed in an anesthesia box, and the sevoflurane vaporizer was adjusted to the required concentration and passed into the anesthesia box through a pipeline. The temperature in the box was maintained at 37±1°C by a heating blanket. The gas in the box was connected to a gas monitor (Vamos, Drager, Germany) by a sampling tube to continuously measure the concentrations of sevoflurane, oxygen, and carbon dioxide in the box. The mice in the control group only inhaled 50% O2. The inhalation time of both groups was 2 hours. After the anesthesia subsided and the righting reflex of the mice recovered, they were returned to the cage. Brain slice electrophysiology and whole-cell patch clamp electrophysiology experiments were carried out using sevoflurane emulsifier.
[0054] Preparation method of sevoflurane emulsifier: Add sevoflurane at a volume ratio of 3% (about 200 mM) into a sealed medium / long chain fat emulsion injection and mix thoroughly.
[0055] 2.2 Ketamine administration method
[0056] Ketamine was diluted to 300 μg / ml with 0.9% saline and injected intraperitoneally at 10 mg / kg.
[0057] 2.3 Blood gas testing
[0058] At the end of ventilation, the needle was inserted vertically at the strongest cardiac beat between the 5th and 6th intercostal space on the left side of the rat's sternum. The PICO 70 blood gas needle is self-priming. After being inserted into the left ventricle, the blood in the empty blood gas needle can be seen to automatically flow in. After collecting 0.3 ml of blood, it was added to the Radiometer ABL80 blood gas analyzer to measure arterial blood gas.
[0059] 2.4 Establishment of chronic stress depression model
[0060] The chronic unpredictable mild stress (CMS) model of depression was used as the modeling method. The CMS model is a commonly used animal model for studying depression. The method for establishing the model is as follows:
[0061] Adult mice were subjected to long-term chronic stress, and were randomly given one type of stress every day, including: empty cage, slanted cage, wet cage, restraint, white noise, day and night reversal, ice water stimulation and food and water deprivation. After 8 weeks of continuous stress, about 70% of the mice showed obvious depressive-like symptoms.
[0062] 2.5 Animal behavior assessment
[0063] Open field test (OFT): Place the mice in the center of an open field measuring 40 cm × 40 cm × 35 cm and allow them to explore freely for 10 minutes. Use the "Mouse Spontaneous Activity Analysis System" to analyze the spontaneous movement ability of the mice. Record the movement of the mice in the center of the open field to evaluate the anxiety-like behavior of the mice. Record the number of wall climbing by the mice to evaluate the depression-like behavior of the mice.
[0064] Forced swimming test (FST): The mice were pre-swimmed one day in advance. The mice were placed in a transparent cylindrical bucket with an inner diameter of 20 cm and a height of 35 cm. The bucket was filled with water at a temperature of 24°C and a depth of 20 cm. The mice were allowed to adapt for 10 minutes. During the test, the mice swam for 10 minutes under the same conditions as the pre-swimming test, and the immobility time of the mice in the water was counted.
[0065] Sucrose preference test (SPT): Place a bottle of water on each side of the mouse cage 4 days in advance, and adapt for 3 consecutive days. Deprive the mouse of water for 20 hours one day before the test. In the formal test, place a bottle of water and a bottle of 1% sucrose water in the mouse cage. After the mouse drinks water freely for 1 hour, swap the water and sucrose water positions, and drink water freely for another hour. Record the water and sucrose water consumption of the mouse within 2 hours, and calculate the percentage of sucrose water intake in the total intake. The calculation formula is as follows: Sucrose water preference = V 蔗糖溶液 / (V 蔗糖溶液 +V 正常水 )×100%.
[0066] 2.6 HEK 293 cell culture
[0067] The culture environment is: DMEM / F12 (Gibco), 10% fetal bovine serum (Gibco), 10U / mL penicillin-streptomycin (Cellgro), 37°C / 5% CO2 constant temperature cell culture incubator. NMDA subunit and green fluorescent protein plasmids are transfected into HEK293 cells at a ratio of GluN1 / GluN2 / GFP=1:1:1, and the cell culture time after transfection is 12-16 hours.
[0068] 2.7 Brain drug delivery
[0069] Mice were anesthetized by intraperitoneal injection of sodium pentobarbital 80 mg / kg, and the mouse head was fixed by a brain stereotaxic instrument. According to the mouse brain atlas, the coordinates of the mPFC were: A / P: +1.8mm, M / L: ±0.5mm, D / V: -2.5mm; the coordinates of the buried tube were: A / P: +1.8mm, M / L: ±0.5mm, D / V: -1.5mm; the buried tube was fixed with dental cement. One week later, the mPFC brain region was administrated, and 0.5μL of the drug was injected by a microinjection pump at a rate of 0.15μL / min.
[0070] 2.8 Whole-cell patch clamp recording of NMDA subtype currents
[0071] Among HEK 293 cells expressing GFP, cells with plump morphology were selected, and glass electrodes (3-6 MΩ) were placed close to the cells to form a whole-cell recording mode. 200 μM glutamate + 30 μM glycine were used to induce currents of various NMDA subtypes, and the inhibition of sevoflurane on various NMDA subtypes was measured.
[0072] Statistical analysis
[0073] All experimental data were expressed as mean ± SEM, and arterial blood gas data were expressed as mean ± SD. Two-way ANOVA with repeated measurement analysis was used for rat behavior and sevoflurane concentration-dose effect, and p < 0.05 was considered statistically significant; independent-samples T test was used for arterial blood gas data, and p < 0.05 was considered statistically significant. Statistical analysis was performed using SPSS 19.0 (SPSS Inc., Chicago, IL, USA) statistical software.
[0074] 3. Experimental results
[0075] 3.1 Antidepressant effect of repeated exposure to different concentrations of sevoflurane
[0076] Normal C57BL / 6 mice were used as a model and ketamine was used as a positive control drug for rapid antidepressant effects. The antidepressant effects of different concentrations and frequencies of sevoflurane administration were evaluated and combined with the results of blood gas analysis.
[0077] The repeated exposure mode of sevoflurane was adopted: 3 consecutive days, 2 hours a day, the exposure concentration of sevoflurane was 0.5%, 1%, and 3% respectively; ketamine was used as the positive control drug, and the administration method was 10 mg / kg intraperitoneal injection. The mice were randomly divided into 5 groups, 0.5% sevoflurane group (0.5% sevo group, n=14), 1% sevoflurane group (1% sevo group, n=13), 3% sevoflurane group (3% sevo group, n=13), ketamine group (10 mg / kg, n=12) and control group (50% O2+50% N2, n=14). Immediately after the completion of administration, some mice underwent arterial blood gas analysis, and behavioral experiments were performed 24 hours later. The behavioral content included open field and forced swimming tests to evaluate the antidepressant effect of repeated exposure of different concentrations of sevoflurane.
[0078] Open field test: 24 hours after drug administration, an open field test was performed to detect changes in the mice's autonomous movement ability. The results showed that there was no statistical difference in the total distance traveled every 2 minutes within 10 minutes among the mice in each group ( Figure 1 (a) shows that repeated exposure to 0.5%, 1%, and 3% sevoflurane and a single administration of 10 mg / kg ketamine did not affect the voluntary movement ability of mice. The percentage of central travel in the 1% sevoflurane group during the 4-6 minute period was significantly higher than that in the control group ( Figure 1 Middle b), suggesting that 1% sevoflurane may induce anxiolytic effects.
[0079] Forced swimming test: Forced swimming test was performed 24 hours and one week after drug administration. The results at both time points showed that the immobility time of mice in the 1% sevoflurane group, 3% sevoflurane group, and ketamine group was significantly shorter than that in the control group. There was no statistical difference between the mice in the 0.5% sevoflurane group and the control group ( Figure 2 The results showed that repeated exposure to 1% and 3% sevoflurane for 24 hours can produce significant antidepressant effects, similar to the antidepressant effect of a single dose of 10 mg / kg ketamine. The immobility time continued to decrease in a dose-dependent manner, and the antidepressant effect lasted for more than 1 week.
[0080] Blood gas analysis: In order to avoid the interference of hypoxia, carbon dioxide accumulation and acidosis caused by hypotension, respiratory depression and other factors caused by anesthetics on the research results, arterial blood gas analysis was performed immediately after the mice were dosed. The results showed that the pH value of mice in the 3% sevoflurane group was significantly lower than that of the control group, and pCO2 was significantly higher than that of the control group (Table 1), indicating that mice in the 3% sevoflurane group had severe carbon dioxide accumulation and acidosis. Therefore, repeated exposure to 3% sevoflurane is not recommended to minimize the impact on the ventilation and internal environment of mice. When using 1% sevoflurane, mice will not experience severe side effects such as carbon dioxide accumulation and acidosis.
[0081] Table 1. Blood gas analysis immediately after drug administration
[0082]
[0083] Note: Data are expressed as mean ± standard deviation.
[0084] Independent sample t test was used; compared with the control group, *p<0.05, **p<0.01. pH: pH; pCO2: partial pressure of carbon dioxide; pO2: partial pressure of oxygen.
[0085] Based on the above research results, repeated exposure to 0.5% sevoflurane does not produce an antidepressant effect, repeated exposure to 3% sevoflurane can cause severe carbon dioxide accumulation and acidosis in mice, and repeated exposure to sub-anesthetic concentration (1%) sevoflurane can better produce a rapid antidepressant effect.
[0086] 3.2. Evaluation of the antidepressant effect of a single exposure to subanesthetic concentration (1%) sevoflurane
[0087] This study investigated the effect of a single exposure to 1% (sub-anesthetic concentration) sevoflurane on its antidepressant effect.
[0088] Using normal mice as a model and ketamine as a positive control drug, the mice were randomly divided into 3 groups: 1% sevoflurane single exposure group (1% sevo group, n=12), ketamine group (10 mg / kg, n=12) and control group (50% O2+50% N2, n=12). Behavioral experiments were performed 24 hours after administration, including open field and forced swimming tests, to evaluate the antidepressant effect of 1% sevoflurane single exposure.
[0089] Open field test: 24 hours after drug administration, an open field test was performed to detect changes in the mice's autonomous movement ability. The results showed that there was no statistical difference in the total distance traveled every 2 minutes within 10 minutes among the mice in each group ( Figure 3(a) indicates that a single exposure to 1% sevoflurane and a single administration of 10 mg / kg ketamine did not affect the voluntary movement ability of mice. There was no statistical difference in the percentage of central distance every 2 minutes within 10 minutes among the mice in each group ( Figure 3 Middle b) indicates that a single exposure to 1% sevoflurane cannot produce anxiolytic effects.
[0090] Forced swimming test: Forced swimming test was performed 24 hours after drug administration to count the immobility time of mice. The results (the inserted numbers are the number of mice in each group participating in the test) showed that the immobility time of mice in the ketamine group was significantly less than that of the control group. There was no statistical difference between the mice in the 1% sevoflurane single exposure group and the control group ( Figure 4 ), suggesting that a single exposure to 1% sevoflurane does not produce an antidepressant effect.
[0091] 3.3. Subanesthetic concentration (1%) sevoflurane rapidly and persistently reverses CMS-induced depressive-like behavior
[0092] The above results indicate that repeated exposure to subanesthetic concentration (1%) sevoflurane can better produce rapid antidepressant effects in the normal C57BL / 6 mouse model. This experiment evaluated the antidepressant effect of repeated exposure to 1% sevoflurane in the chronic unpredictable mild stress (CMS) depression model. The CMS depression model is one of the most commonly used models for depression research. It has good face validity, construct validity, and predictive validity. It is an ideal animal model for studying depression and antidepressant efficacy. In this study, after C57BL / 6 mice were subjected to chronic unpredictable mild stress for 8 weeks, behavioral assessments were performed, and most mice showed a depressive-like phenotype. 1% sevoflurane repeated exposure mode: 3 consecutive days, 2 hours a day, ketamine was used as a positive control drug, and the administration method was 10 mg / kg intraperitoneal injection. Mice with depressive phenotypes were selected and randomly divided into 4 groups: CMS+1% sevoflurane group (CMS+1% sevo, n=8), CMS+ketamine group (CMS+10mg / kg Keta, n=8), CMS group (n=8) and control group (50% O2+50% N2, n=11). Three behavioral tests, including open field test, sucrose water preference test and forced swimming test, were performed before administration to determine the baseline value; the above behavioral tests were repeated 24 hours and 2 weeks after the completion of administration. Through the above experiments, the antidepressant effect of repeated exposure to 1% sevoflurane was further evaluated.
[0093] Open field test: The open field test was performed before administration to determine the baseline value; the open field test was repeated 24 hours and 2 weeks after administration. The results showed that there was no difference in the total distance traveled within 10 minutes between the groups of mice before administration, 24 hours after administration, and 2 weeks after administration ( Figure 5 (a), indicating that there was no difference in the motor ability of mice in each group. The central travel percentage of mice in the CMS+1% sevoflurane group was significantly higher than that in the control group, and there was no statistical difference between the other groups and the control group ( Figure 5 b), indicating that 1% sevoflurane may induce anxiolytic effects. The above behavioral tests were performed after the model was successfully established and before drug intervention, and the tests were repeated 24 hours and 2 weeks after drug intervention.
[0094] Sucrose water preference test: Sucrose water preference test was performed before administration to determine the basal value; sucrose water preference test was repeated 24 hours and 2 weeks after administration. The results showed that the percentage of sucrose water intake of CMS mice before administration was significantly lower than that of the control group, indicating that CMS mice had already shown anhedonia before administration and the CMS model was successfully established; 24 hours and 2 weeks after administration, the percentage of sucrose water intake of mice in the 1% sevoflurane group and ketamine group was significantly higher than that in the CMS group, and there was no statistical difference compared with the control group ( Figure 6 ), indicating that repeated exposure to 1% sevoflurane and 10 mg / kg ketamine reversed the reduction in sucrose intake induced by CMS, and the effect could last for 2 weeks. The above behavioral tests were performed after the model was successfully established and before drug intervention, and the tests were repeated 24 hours and 2 weeks after drug intervention.
[0095] Forced swimming test: Forced swimming test was performed before drug administration to determine the basal value; the forced swimming test was repeated 24 hours and 2 weeks after drug administration. The results showed that the immobility time of CMS mice before drug administration was significantly higher than that of the control group, indicating that CMS mice had shown despair behavior before drug administration and the CMS model was successfully established; 24 hours and 2 weeks after drug administration, the immobility time of mice in the 1% sevoflurane group and ketamine group was significantly lower than that of the CMS group, and there was no statistical difference compared with the control group ( Figure 7 ), indicating that repeated exposure to 1% sevoflurane and 10mg / kg ketamine reversed the increase in immobility time induced by CMS, and the effect could last for more than 2 weeks. The above behavioral tests were performed after the model was successfully established and before drug intervention, and the tests were repeated 24 hours and 2 weeks after drug intervention.
[0096] Example 2
[0097] In vitro electrophysiological test: An in vitro expression system was used to express GluN2A / B / C / D-containing NMDARs in HEK 293 cell lines, so that the currents of each NMDAR subtype could be recorded separately. Figure 8 As shown, ad shows the effect of sevoflurane on the four NMDA receptor subunits (sevoflurane: 1 mM in 200 μM glutamate and 20 μM glycine vs. control group: 200 μM glutamate and 20 μM glycine). e shows the concentration-effect relationship of sevoflurane on GluN1 / GluN2D (IC 50 =1.65 mM, n=6) was significantly more potent than GluN1 / GluN2C (IC 50 =18.87 mM, n=5), and had no significant inhibitory effect on GluN1 / GluN2A and GluN1 / GluN2B. In other words, the inhibitory intensity of sevoflurane on NMDAR containing GluN2D subunit was significantly greater than that on NMDAR containing other GluN2 subunits, indicating that sevoflurane has a selective inhibitory effect on GluN2D.
[0098] Multiplex fluorescence in situ hybridization: Multiplex fluorescence in situ hybridization was used to detect the cell-specific expression of GluN2D mRNA in the mPFC. Fig. 9 The results showed that GluN2D in mPFC was specifically expressed in interneurons (co-localized with interneurons but not with pyramidal neurons).
[0099] Open field test: Normal mice were randomly divided into a 1% sevoflurane repeated exposure group and a control group. The non-NMDAR subunit selective inhibitor MK 801, the GluN2D specific antagonist QNZ 46, and the drug solvent DMSO were injected into the mPFC brain region of the mice, and the open field test was performed 30 minutes after repeated exposure to 1% sevoflurane to detect changes in the mice's motor ability. Fig.10 There was no statistical difference in the total distance traveled by each group of mice within 10 minutes, indicating that repeated exposure to 1% sevoflurane would not affect the motor ability of mice after pretreatment with the non-NMDAR subunit selective inhibitor MK 801 and the GluN2D specific antagonist QNZ 46.
[0100] Forced swimming test: Normal mice were randomly divided into a 1% sevoflurane repeated exposure group and a control group. NMDAR nonspecific subunit inhibitor MK 801, GluN2D specific antagonist QNZ 46 and drug solvent DMSO were injected into the mPFC brain region of the mice, respectively. Forced swimming test was performed 30 minutes after repeated exposure to 1% sevoflurane. Fig.11The results showed that the immobility time of mice injected with DMSO in the brain area was significantly reduced 30 minutes after repeated exposure to 1% sevoflurane, indicating that DMSO had no effect on the antidepressant effect of sevoflurane. The immobility time of mice pretreated with only the NMDAR nonspecific subunit inhibitor MK 801 was significantly lower than that of mice pretreated with only DMSO, indicating that MK 801 itself can produce significant antidepressant effects. The immobility time of mice pretreated with the GluN2D specific antagonist QNZ 46 after repeated exposure to 1% sevoflurane was not significantly different from that of mice pretreated with only DMSO, indicating that QNZ 46 can block the antidepressant effect of sevoflurane.
[0101] Tail suspension test: Normal mice were randomly divided into a 1% sevoflurane repeated exposure group and a control group. NMDAR nonspecific subunit inhibitor MK 801, GluN2D specific antagonist QNZ 46 and drug solvent DMSO were injected into the mPFC brain region of the mice, respectively. The tail suspension test was performed 30 minutes after repeated exposure to 1% sevoflurane. Fig.12 The results showed that the immobility time of mice injected with DMSO in the brain area was significantly reduced 30 minutes after repeated exposure to 1% sevoflurane, indicating that DMSO had no effect on the antidepressant effect of sevoflurane. The immobility time of mice pretreated with MK 801, a nonspecific subunit inhibitor of NMDAR, and then repeatedly exposed to 1% sevoflurane was significantly lower than that of mice pretreated with DMSO alone, indicating that MK 801 itself can produce significant antidepressant effects. The immobility time of mice pretreated with QNZ 46, a specific antagonist of GluN2D, was not significantly different from that of mice pretreated with DMSO alone 30 minutes after repeated exposure to 1% sevoflurane, indicating that QNZ 46 can block the antidepressant effect of sevoflurane.
[0102] Brain slice electrophysiological experiment: First, the EGPF-labeled interneurons of EGFP-GAD67 transgenic mice and the EGPF-labeled pyramidal neurons of EGFP-Camk2α transgenic mice were verified by immunofluorescence technology. In the mPFC brain slices of EGFP-GAD 67 transgenic mice, the changes in the total APs discharge rate and cluster discharge rate of interneurons before 1.0mM sevoflurane intervention (basal value), after intervention and after washout were compared by whole-cell patch clamp technology. The results showed that after 1.0mM sevoflurane intervention, the total APs discharge rate and cluster discharge rate of interneurons were significantly decreased compared with those before intervention (basal value), indicating that 1.0mM sevoflurane significantly inhibited the APs discharge frequency and cluster discharge rate of interneurons; the total APs discharge rate and cluster discharge rate after sevoflurane washout were higher than before washout, but still significantly lower than the basal value, indicating that the total APs discharge rate and cluster discharge rate can be partially restored by ACSF washing ( Fig.13a, c). The total APs discharge rate and cluster discharge rate of interneurons after 3μM QNZ 46 intervention were significantly lower than those before intervention (basal value). The total APs discharge rate and cluster discharge rate after washout were still significantly lower than the basal value, but higher than those before washout, suggesting that the GluN2D-specific antagonist QNZ 46 mimics the inhibitory effect of 1.0mM sevoflurane on interneurons ( Fig.13 (b, d).
[0103] In the mPFC brain slices of EGFP-Camk2α transgenic mice, the whole-cell patch clamp technique was used to compare the changes in the total APs discharge rate of pyramidal neurons before (basal value), after intervention and after washout with 1.0mM sevoflurane. The results showed that after 1.0mM sevoflurane intervention, the total APs discharge rate of pyramidal neurons was significantly increased compared with that before intervention (basal value), indicating that 1.0mM sevoflurane increased the APs discharge frequency of pyramidal neurons; the total APs discharge rate after sevoflurane washout was lower than that before washout, but still significantly higher than the basal value, indicating that the total APs discharge rate can be partially restored by ACSF washing ( Fig.13 e). 3μM QNZ 46 significantly increased the total APs firing rate of pyramidal neurons; after 3μM QNZ pretreatment, 1.0mM sevoflurane intervention did not increase the total APs firing rate of pyramidal neurons, suggesting that 3μM GluN2D-specific antagonist QNZ 46 can block the enhancing effect of 1.0mM sevoflurane on APs of pyramidal neurons ( Fig.13 (f)
[0104] discuss
[0105] Depression has a high incidence and disability rate, especially major depressive disorder (MDD), which is more harmful. However, the first-line antidepressant monoamine oxidase inhibitors commonly used in clinical practice have the defects of delayed onset and ineffectiveness. Therefore, the development of rapid antidepressant drugs targeting new targets is an urgent need for clinical treatment.
[0106] In recent years, the research and mechanism exploration of new rapid antidepressant drugs targeting the glutamate neurotransmitter system has become a research hotspot at home and abroad. As one of the most important members of glutamate receptors, N-methyl-D-aspartate receptor (NMDAR) plays a key role in synaptic plasticity and neural network transmission. The imbalance of central "excitation-inhibition" caused by NMDAR dysfunction is closely related to the occurrence of depression. In 2019, the FDA approved the NMDAR competitive antagonist ketamine (a classic general anesthetic) for the clinical treatment of drug-resistant depression, becoming the first antidepressant with a new mechanism of action approved by the FDA in the past 30 years. Therefore, it is a major breakthrough in the field of antidepressant treatment. However, since ketamine is a non-subunit selective NMDAR receptor antagonist, it has side effects such as hallucinations, dissociation and addiction, which severely limits its clinical application and is currently limited to use in monitored environments in medical institutions. Today, in the study of rapid antidepressant targeting NMDAR, how to reduce side effects is still a scientific problem that needs to be solved urgently.
[0107] NMDAR is an ion channel receptor with 7 subunits, including GluN1, GluN2A-2D, and GluN3A-3B. Its functional form is mostly composed of 2 GluN1 and 2 GluN2 (tetramer). NMDAR can present different functional characteristics according to the difference in subunit composition, brain regions, cell types, and subcellular structure distribution, and is a reliable potential target for rapid and sustained antidepressant effects.
[0108] After extensive and intensive research, the inventors unexpectedly discovered through whole-cell patch clamp technology that sevoflurane has a significantly stronger inhibitory effect on NMDAR containing GluN2D subunits than other NMDAR combinations containing GluN2 subunits, that is, it can selectively inhibit NMDAR containing GluN2D subunits. GluN2D is specifically expressed in fast-discharging interneurons (PV neurons) in the cortical limbic brain area. Sevoflurane regulates the function of interneurons in the cortical limbic system by selectively inhibiting NMDAR containing GluN2D subunits.
[0109] The inventors further conducted research at the animal level: normal mice were randomly divided into a 1% sevoflurane repeated exposure group and a control group, and the NMDA receptor nonspecific subunit inhibitor MK 801, the GluN2D specific antagonist QNZ 46 and the drug solvent DMSO were injected into the mPFC brain region of the mice, respectively. The open field test, tail suspension test and forced swimming test were performed 30 minutes after the repeated exposure to 1% sevoflurane. Through the above-mentioned behavioral tests combined with brain slice electrophysiological technology, it was confirmed that the sub-anesthetic dose of sevoflurane exerted a rapid antidepressant effect by inhibiting NMDAR containing GluN2D subunits.
[0110] Sevoflurane is a general anesthetic widely used in surgical anesthesia. Compared with other anesthetics, sevoflurane has been shown to be more effective and safer. The results of the present application show that repeated exposure to subanesthetic concentrations (1%) of sevoflurane can induce a rapid antidepressant effect that can last for more than 2 weeks. For patients who do not respond to ketamine treatment or who have excessive side effects from ketamine treatment, treatment with subanesthetic concentrations (1%) of sevoflurane can produce a rapid antidepressant effect without side effects. In addition, because repeated exposure to subanesthetic concentrations (1%) of sevoflurane can produce a rapid antidepressant effect that can last for more than 2 weeks, it is also suitable for the treatment / prevention of refractory depression, major depression (including major depression with suicidal tendencies), resistant depression, and depression that is not responding to monoamine oxidase inhibitors.
[0111] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A use of sevoflurane, characterized in that: Used for preparing drugs for treating or preventing depression; or used for preparing drugs for selectively inhibiting NMDA receptors containing GluN2D subunits.
2. The use according to claim 1, characterized in that The depression is selected from the group consisting of: drug-resistant depression, refractory depression, and depression that is ineffective with monoamine oxidase inhibitors.
3. The use according to claim 2, characterized in that The major depression is major depression with suicidal tendency.
4. The use according to claim 1, characterized in that The drug is used to treat patients who are not responsive to monoamine oxidase inhibitors; or, the drug is used to treat patients who are not responsive to ketamine treatment or patients who have excessive side effects from ketamine treatment.
5. The use according to claim 1, characterized in that The drug is used to treat patients with abnormal GluN2D subunit or abnormal GluN1 / GluN2D receptor.
6. The use according to claim 1, characterized in that The sevoflurane is used to inhibit GluN1 / GluN2D receptors.
7. A method for inhibiting the activity of GluN2D subunit in vitro, characterized in that: The method comprises contacting cells expressing GluN2D subunit with sevoflurane, thereby inhibiting the activity of the GluN2D subunit.
8. The method according to claim 7, characterized in that The method is non-therapeutic, non-diagnostic.
9. A method for inhibiting the activity of GluN1 / GluN2D receptors in vitro, characterized in that: The method comprises contacting a cell expressing a GluN1 / GluN2D receptor with sevoflurane, thereby inhibiting the activity of the GluN2D subunit.
10. The method according to claim 9, characterized in that The method is non-therapeutic, non-diagnostic.
